Published in Trends Cardiovasc Med on July 01, 2011
Use of a whole-slide imaging system to assess the presence and alteration of lymphatic vessels in joint sections of arthritic mice. Biotech Histochem (2012) 0.80
Mobilization of lymphatic endothelial precursor cells and lymphatic neovascularization in primary Sjögren's syndrome. J Cell Mol Med (2016) 0.78
Prox1 function is required for the development of the murine lymphatic system. Cell (1999) 7.57
Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol (2003) 7.42
Lymphangiogenesis: Molecular mechanisms and future promise. Cell (2010) 5.84
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest (2004) 5.59
An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J (2002) 5.07
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science (1998) 5.07
Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J (2002) 3.99
T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J (2003) 3.82
Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood (2010) 3.82
Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest (2005) 3.77
Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science (2003) 3.60
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res (2001) 3.38
Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood (2010) 3.35
Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med (2004) 3.32
Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A (2008) 3.27
Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med (2002) 3.16
Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn (2002) 3.10
Sox18 induces development of the lymphatic vasculature in mice. Nature (2008) 2.91
Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. Genes Dev (2008) 2.91
Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med (2006) 2.56
VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood (2002) 2.52
Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol (2008) 2.49
Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood (2004) 2.30
FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol (2009) 2.17
Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood (2010) 2.04
VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest (2003) 1.84
Concise review: Circulating endothelial progenitor cells for vascular medicine. Stem Cells (2011) 1.80
Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem (2010) 1.77
Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem (2003) 1.67
Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J (2002) 1.67
Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res (2004) 1.57
D2-40 immunohistochemistry--so far! Adv Anat Pathol (2009) 1.57
Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood (2006) 1.52
Tumor metastasis and the lymphatic vasculature. Int J Cancer (2009) 1.51
COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model. Proc Natl Acad Sci U S A (2006) 1.42
Plasticity of marrow-derived stem cells. Gene Ther (2002) 1.41
Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels. Blood (2005) 1.36
Prox1 physically and functionally interacts with COUP-TFII to specify lymphatic endothelial cell fate. Blood (2008) 1.36
Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax. Dev Biol (2011) 1.35
Minimal contribution of marrow-derived endothelial precursors to tumor vasculature. J Immunol (2005) 1.31
Vascular endothelial growth factor-C accelerates diabetic wound healing. Am J Pathol (2006) 1.30
Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation (2008) 1.22
COUP-TFII regulates the functions of Prox1 in lymphatic endothelial cells through direct interaction. Genes Cells (2009) 1.22
Myeloid cells contribute to tumor lymphangiogenesis. PLoS One (2009) 1.22
VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis. Cell Res (2010) 1.16
Phospholipase Cgamma2 is necessary for separation of blood and lymphatic vasculature in mice. Development (2008) 1.16
The Notch1-Dll4 signaling pathway regulates mouse postnatal lymphatic development. Blood (2011) 1.13
9-cis retinoic acid promotes lymphangiogenesis and enhances lymphatic vessel regeneration: therapeutic implications of 9-cis retinoic acid for secondary lymphedema. Circulation (2012) 1.11
Podoplanin-expressing cells derived from bone marrow play a crucial role in postnatal lymphatic neovascularization. Circulation (2010) 1.07
Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J (2004) 0.94
Interleukin-7 partially rescues B-lymphopoiesis in osteopetrotic oc/oc mice through the engagement of B220+ CD11b+ progenitors. Exp Hematol (2006) 0.86
Stem cell plasticity: the debate begins to clarify. Stem Cell Rev (2005) 0.80
Progressive and controlled development of mouse dendritic cells from Flt3+CD11b+ progenitors in vitro. J Immunol (2005) 0.79
Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J Exp Med (2007) 2.25
Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat Med (2005) 2.24
Human peripheral blood-derived CD31+ cells have robust angiogenic and vasculogenic properties and are effective for treating ischemic vascular disease. J Am Coll Cardiol (2010) 1.92
Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ Res (2006) 1.63
Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. J Exp Med (2006) 1.56
Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation (2005) 1.28
Subtelomeric hotspots of aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to pluripotency. Nat Cell Biol (2013) 1.27
The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A. J Clin Invest (2005) 1.26
Sonic hedgehog induces arteriogenesis in diabetic vasa nervorum and restores function in diabetic neuropathy. Arterioscler Thromb Vasc Biol (2004) 1.17
Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy. Circulation (2009) 1.10
Podoplanin-expressing cells derived from bone marrow play a crucial role in postnatal lymphatic neovascularization. Circulation (2010) 1.07
Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy. Stem Cells (2009) 1.04
Crystal structure of the N-terminal domain of anaphase-promoting complex subunit 7. J Biol Chem (2008) 0.96
Analysis of estrogen-regulated genes in mouse uterus using cDNA microarray and laser capture microdissection. J Endocrinol (2004) 0.96
Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc levels in mouse brain. J Biol Chem (2003) 0.95
Genome sequence of Lactobacillus johnsonii PF01, isolated from piglet feces. J Bacteriol (2011) 0.91
Differential proteome profiling using iTRAQ in microalbuminuric and normoalbuminuric type 2 diabetic patients. Exp Diabetes Res (2012) 0.90
Overexpression of catalase in myeloid cells causes impaired postischemic neovascularization. Arterioscler Thromb Vasc Biol (2011) 0.89
Autologous transplantation of endothelial progenitor cells genetically modified by adeno-associated viral vector delivering insulin-like growth factor-1 gene after myocardial infarction. Hum Gene Ther (2010) 0.89
Estrogen regulates the expression of the small proline-rich 2 gene family in the mouse uterus. Mol Cells (2004) 0.87
Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia. Vasc Med (2005) 0.87
Epigenetic landscape of pluripotent stem cells. Antioxid Redox Signal (2012) 0.86
Molecular cloning and characterization of a bile salt hydrolase from Lactobacillus acidophilus PF01. J Microbiol Biotechnol (2008) 0.83
Advances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy. Regen Med (2011) 0.83
Generation of induced pluripotent stem cells from somatic cells. Prog Mol Biol Transl Sci (2012) 0.83
All in the family: VEGF-B joins the ranks of proangiogenic cytokines. Circ Res (2003) 0.82
Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. J Cereb Blood Flow Metab (2006) 0.82
Analysis of differential proteomes of induced pluripotent stem cells by protein-based reprogramming of fibroblasts. J Proteome Res (2011) 0.82
Repair of ischemic heart disease with novel bone marrow-derived multipotent stem cells. Cell Cycle (2005) 0.81
Unusual presentation of Ewing sarcoma in the adrenal gland: a secondary malignancy from a survivor of Burkitt lymphoma. Jpn J Clin Oncol (2013) 0.81
Induction of pluripotency in bone marrow mononuclear cells via polyketal nanoparticle-mediated delivery of mature microRNAs. Biomaterials (2013) 0.80
Diabetic Mesenchymal Stem Cells Are Ineffective for Improving Limb Ischemia Due to Their Impaired Angiogenic Capability. Cell Transplant (2014) 0.80
Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves. Endocr Metab Immune Disord Drug Targets (2012) 0.79
Effects of palmitic acid on TNF-α-induced cytotoxicity in SK-Hep-1 cells. Toxicol In Vitro (2012) 0.78
Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Res (2013) 0.78
Treatment of thoracic aortic dissection with stent-grafts: midterm results. J Endovasc Ther (2002) 0.78
Bone marrow-derived stem cell therapy in ischemic heart disease. Regen Med (2006) 0.76
Bone Marrow-Derived Mesenchymal Stem Cells Improve Diabetic Neuropathy by Direct Modulation of Both Angiogenesis and Myelination in Peripheral Nerves. Cell Transplant (2015) 0.76
Synergism of hematopoietic cytokines for infarct repair. Circ Res (2006) 0.75
Derivation and characterization of bone marrow-derived multipotent stem cells. Exp Hematol (2006) 0.75
Angiogenesis in the Transplanted Donor Graft after Living-Donor Liver Transplantation. Transplantation (2017) 0.75
Electrical properties of magnesium incorporated zinc tin oxide thin film transistors by solution process. J Nanosci Nanotechnol (2013) 0.75